Pfizer Inc.  

(Public, NYSE:PFE)   Watch this stock  
Find more results for PFE
34.43
+0.07 (0.20%)
Real-time:   1:41PM EDT
NYSE real-time data - Disclaimer
Currency in USD
Range 34.23 - 34.49
52 week 27.51 - 35.53
Open 34.32
Vol / Avg. 6.37M/24.30M
Mkt cap 211.70B
P/E 23.81
Div/yield 0.28/3.25
EPS 1.45
Shares 6.16B
Beta 0.77
Inst. own 75%
Jul 27, 2015
Q2 2015 Pfizer Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jun 2, 2015
Pfizer Inc Corporate Call - Oncology Business Review and ASCO Data Presentations - 4:30PM EDT - Add to calendar
Apr 28, 2015
Q1 2015 Pfizer Inc Earnings Call
Apr 28, 2015
Q1 2015 Pfizer Inc Earnings Release
Apr 23, 2015
Pfizer Inc Annual Shareholders Meeting
Apr 2, 2015
Pfizer Inc at Goldman Sachs Biosimilars Conference
Mar 24, 2015
Pfizer Inc at Biotechnology Industry Organization (BIO) Asia International Conference
Mar 3, 2015
Pfizer Inc at Cowen Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin 21.87% 18.39%
Operating margin 29.11% 25.66%
EBITD margin - 40.72%
Return on average assets 5.78% 5.34%
Return on average equity 13.72% 12.32%
Employees 78,300 -
CDP Score - 92 B

Address

235 E 42ND ST
NEW YORK, NY 10017-5703
United States - Map
+1-212-5732323 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
About Company - Wikipedia

Description

Pfizer Inc. is a bio pharmaceutical company. The company applies science and resources to discover, develop and manufacture healthcare products. The Company provides medicines, vaccines and consumer healthcare products. The Company operates its business through three operating segments, which include Global Innovative Pharmaceutical segment (GIP); the Global Vaccines, Oncology and Consumer Healthcare segment (VOC), and the Global Established Pharmaceutical segment (GEP). The Company provides medical information to healthcare providers, patients and other parties, transparency and disclosure activities, clinical trial results publication, grants for healthcare quality improvement and medical education, partnerships with global public health and medical associations, regulatory inspection readiness reviews, internal audits of Pfizer-sponsored clinical trials and internal regulatory compliance processes.

Officers and directors

Ian C. Read Chairman of the Board, Chief Executive Officer
Age: 61
Bio & Compensation  - Reuters
Frank A. D'Amelio Chief Financial Officer, Executive Vice President - Business Operations
Age: 57
Bio & Compensation  - Reuters
Albert Bourla Group President - Vaccines, Oncology and Consumer Healthcare Business
Age: 53
Bio & Compensation  - Reuters
Mikael Dolsten M.D., Ph.D. President - Worldwide Research and Development
Age: 56
Bio & Compensation  - Reuters
Geno J. Germano Group President - Global Innovative Pharma Business
Age: 54
Bio & Compensation  - Reuters
John D Young Group President - Global Established Pharma Business
Age: 50
Bio & Compensation  - Reuters
Rady A. Johnson II Executive Vice President, Chief Compliance and Risk Officer
Age: 53
Bio & Compensation  - Reuters
Douglas M. Lankler Executive Vice President, General Counsel
Age: 49
Bio & Compensation  - Reuters
Charles H. Hill III Executive Vice President - Worldwide Human Resources
Age: 59
Bio & Compensation  - Reuters
Freda C. Lewis-Hall M.D. Executive Vice President, Chief Medical Officer
Age: 60
Bio & Compensation  - Reuters